The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

The approval is supported by data from the COBLT study, FDA dockets and public information, and an observational database.

A dispute over the U.S. Food and Drug Administration's refusal to let two e-cigarette companies sell flavored vape products ...

A clinical trial study will give vets medical and commercial-grade cannabis products to look at “real-world” use and its ...

The device is established in Europe, where the company said it has a 60% market share, but will be the first product of its ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

The UbiqVue 2A multi-parameter system biosensor is worn on the chest and collects biodata across 13 monitored parameters.

More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...

The U.S. Supreme Court will hear arguments Monday on whether to reinstate a federal ban on sweet-flavored vaping products.

Acoramidis is the first FDA-approved treatment for ATTR-CM with ... becomes the first and only approved product with a label specifying near-complete stabilization of TTR. "ATTR-CM is a ...

The InPen app syncs with the Smart MDI system via Bluetooth, allowing for real-time monitoring of insulin doses and glucose.